ACOX1 and metabolic dysfunction-associated steatotic liver disease: In non-alcoholic fatty liver disease (NAFLD), where a triglyceride accumulation in hepatocytes (hepatic steatosis) is present, Kohjima et al. demonstrated that the expression of ACOX-1 was increased twofold compared with that in the normal liver [19].